Is CASBF or XYLD a better dividend investment in 2026?

CASBF currently yields 51.81% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: CASBF offers higher current income.

What is the dividend yield difference between CASBF and XYLD?

CASBF has a forward dividend yield of 51.81% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 40.83 percentage points.

Home › Compare › CASBF vs XYLD

CASBF vs XYLD: Dividend Comparison 2026

CASBF yields 51.81% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CASBF wins by $4.7K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CASBF

● Live price

51.81%

Share price

$3.86

Annual div

$2.00

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.0K

Annual income

$7.71

Full CASBF calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — CASBF vs XYLD

📍 CASBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CASBF	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CASBF + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CASBF pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF

Annual income on $10K today (after 15% tax)

$4,404.15/yr

After 10yr DRIP, annual income (after tax)

$6.55/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, XYLD beats the other by $2,729.61/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + XYLD for your $10,000?

CASBF: 50%XYLD: 50%

100% XYLD50/50100% CASBF

Portfolio after 10yr

$27.6K

Annual income

$1,613.36/yr

Blended yield

5.84%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys

XYLD buys

No recent congressional trades found for CASBF or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCASBFXYLD

Forward yield	51.81% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	-50%	0% ✓
Portfolio after 10y	$30.0K ✓	$25.3K
Annual income after 10y	$7.71	$3,219.02 ✓
Total dividends collected	$6.0K	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: CASBF vs XYLD ($10,000, DRIP)

Year	CASBF Portfolio	CASBF Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$13,291	$2,590.67	$10,818	$1,098.39	+$2.5K → CASBF
2	$15,830	$1,608.96	$11,738	$1,222.51	+$4.1K → CASBF
3	$17,834	$895.50	$12,774	$1,364.64	+$5.1K → CASBF
4	$19,553	$471.42	$13,944	$1,527.86	+$5.6K → CASBF
5	$21,164	$241.53	$15,270	$1,715.87	+$5.9K → CASBF
6	$22,767	$122.16	$16,775	$1,933.09	+$6.0K → CASBF
7	$24,422	$61.41	$18,490	$2,184.87	+$5.9K → CASBF
8	$26,163	$30.78	$20,450	$2,477.63	+$5.7K → CASBF
9	$28,010	$15.41	$22,697	$2,819.19	+$5.3K → CASBF
10	$29,978	$7.71	$25,280	$3,219.02	+$4.7K → CASBF

CASBF vs XYLD: Complete Analysis 2026

CASBF — Stock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this CASBF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHD CASBF vs JEPI CASBF vs O CASBF vs KO CASBF vs MAIN CASBF vs QYLD CASBF vs JEPQ CASBF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.